Integration of in vivo and in vitro approaches to characterize the toxicity of Antalarmin, a corticotropin-releasing hormone receptor antagonist

Toxicology

Volumn 248, Issue 1, 2008, Pages 8-17

  Horn, Thomas L ^a   Harder, J Brooks ^a   Johnson, William D ^a   Curry, Patrick T ^a   Parchment, Ralph E ^b   Morrissey, Robert L ^c   Mellick, Paul W ^c   Calis, Karim A ^d   Gold, Philip W ^d   Rice, Kenner C ^d   Contoreggi, Carlo ^d   Charney, Dennis S ^d   Cizza, Giovanni ^d   Glaze, Elizabeth R ^d   Tomaszewski, Joseph E ^d   McCormick, David L ^a  

^a IIT RESEARCH INSTITUTE   (United States)

^b SciTech Development   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antalarmin; Bone marrow cytotoxicity; Corticotropin releasing hormone receptor antagonist; Preclinical toxicology

Indexed keywords

ANTALARMIN; CYCLOPHOSPHAMIDE; GAMMA GLUTAMYLTRANSFERASE;

ANEMIA; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CONTROLLED STUDY; CYTOTOXICITY; DOG; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTOXICITY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MALE; MUTAGENICITY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BONE MARROW CELLS; CELL LINE, TUMOR; COLONY-FORMING UNITS ASSAY; DOGS; FEMALE; HUMANS; KIDNEY; LIVER; MALE; MICE; MUTAGENICITY TESTS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PYRIMIDINES; PYRROLES; RATS; RATS, INBRED F344; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SALMONELLA TYPHIMURIUM; VOMITING;

BACTERIA (MICROORGANISMS); CANIS FAMILIARIS; MAMMALIA; RATTUS;

EID: 42749091980     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2008.03.002     Document Type: Article

References (22)

1. Ayala A.R., Pushkas J., Higley J.D., Ronsaville D., Gold P.W., Chrousos G.P., Pacak K., Calis K.A., Gerald M., Lindell S., Rice K.C., and Cizza G. Behavioral, adrenal, and sympathetic responses to long-term administration of an oral corticotropin-releasing hormone receptor antagonist in a primate stress paradigm. J. Clin. Endocrinol. Metab. 89 (2004) 5729-5737
2. Chen, Y.L., 1994. Pyrrolopyrimidines as CRF Antagonists. International Patent WO 94/13676.
3. Chen R., Lewis K.A., Perrin M.H., and Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 8967-8971
4. De Bellis M.D., Gold P.W., Geracioti Jr. T.D., Listwak S.J., and Kling M.A. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am. J. Psychiatry 150 (1993) 656-657
5. Deak T., Nguyen K.T., Ehrlich A.L., Watkins L.R., Spencer R.L., Maier S.F., Licinio J., Wong M.-L., Chrousos G.P., Webster E., and Gold P.W. The impact of the nonepeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140 (1999) 79-86
6. Erickson-Miller C.L., May R.D., Tomaszewski J., Osborn B., Murphy M.J., Page J.G., and Parchment R.E. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother. Pharmacol. 39 (1997) 467-472
7. Habib K.E., Weld K.P., Rice K.C., Pushkas J., Champoux M., Listwak S., Webster E.L., Atkinson A.J., Schulkin J., Contoreggi C., Chrousos G.P., McCann S.M., Suomi S.J., Higley J.D., and Gold P.W. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6079-6084
8. Hayashi M., Sofuni T., and Ishidate Jr. M. An application of acridine orange fluorescent staining to the micronucleus test. Mutat. Res. 120 (1983) 241-247
9. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 33 (1999) 181-214
10. Maron D.M., and Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113 (1983) 173-215
11. National Research Council. Guide for the Care and Use of Laboratory Animals (1996), National Academy Press, Washington, DC
12. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts D.C., Loosen P.T., and Vale W. Elevated concentrations of CSF corticotropin releasing factor-like immunoreactivity in depressed patients. Science 226 (1984) 1342-1344
13. Parchment R.E. Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity. Environ. Health Perspect. 106 Suppl. 2 (1998) 541-557
14. Parchment R.E., Huang M., and Erickson-Miller C.L. Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol. Pathol. 21 (1993) 241-250
15. Parchment R.E., Volpe D.A., LoRusso P.M., Erickson-Miller C.L., Murphy Jr. M.J., and Grieshaber C.K. In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow. J. Natl. Cancer Inst. 86 (1994) 273-280
16. Parchment R.E., Gordon M., Grieshaber C.K., Sessa C., Volpe D., and Ghielmini M. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann. Oncol. 9 (1998) 357-364
17. Pessina A., Albella B., Bayo M., Bueren J., Brantom P., Casati S., Croera C., Gagliardi G., Foti P., Parchment R., Parent-Massin D., Schoeters G., Sibiril Y., Van Den Heuvel R., and Gribaldo L. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol. Sci. 75 (2003) 355-367
18. Plotsky P.M. Pathways to the secretion of adrenocorticotropin: a view from the portal. J. Neuroendocrinol. 3 (1997) 1-9
19. Rivier C., and Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 305 (1983) 325-327
20. Vale W., Spiess J., Rivier C., and Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213 (1981) 1394-1397
21. Webster E.L., Lewis D.B., Torpy D.J., Zachman E.K., Rice K.C., and Chrousos G.P. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137 (1996) 5747-5750
22. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., and Holsboer F. Effects of the high affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34 (2000) 171-181